Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway - Test2 - elhamkhani - TriplyDB

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

http://www.wikidata.org/entity/Q26797238

about

MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis Expression of the lncRNA Maternally Expressed Gene 3 (MEG3) Contributes to the Control of Lung Cancer Cell Proliferation by the Rb Pathway SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation.Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine Activin A programs the differentiation of human TFH cells.TGF-β1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT)Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.Mammary Gland Involution Provides a Unique Model to Study the TGF-β Cancer Paradox.Advances in Immunotherapy for Glioblastoma Multiforme.Mechanism of immune evasion in breast cancer.Efficacy of ALK5 inhibition in myelofibrosis.NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions.Advances in immunotherapy for the treatment of glioblastoma.Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.Pharmacological and immunological targeting of tumor mesenchymalization.Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy.Transforming growth factor-β: A therapeutic target for cancer.Driving cancer evolution.Th22 Cells Form a Distinct Th Lineage from Th17 Cells In Vitro with Unique Transcriptional Properties and Tbet-Dependent Th1 Plasticity Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment.Integrins as Therapeutic Targets: Successes and Cancers.A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.Targeting BRAF-mutant tumours with TGFBR1 inhibitors.Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.Immuno-oncology combinations: raising the tail of the survival curve.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis.Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma.A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives.

P2860

Q27348347-6285DFE4-40F2-44E4-88E1-129EA348598F Q28553467-F3D711FB-5196-423D-A2C8-1DBC2AA68E74 Q33624675-F78E42BA-D5C9-4C50-A045-7ED5B8B4E77A Q33755077-559EB433-0B0E-4CC7-AB13-A6C0FC669BD5 Q36067435-212DB6BC-BD96-4E3A-B644-683505EC70B0 Q36121570-D8782E50-CD01-467F-A199-20B7701E15C4 Q36638387-D3753081-E7C6-4893-800B-AD4F320C2A1B Q37079141-522EA2C7-5F52-4246-AB69-A3EFCF7C77B0 Q37195723-1134B0C8-99F8-437B-9446-ABE9CB4D52F5 Q37488519-3B5FEEED-842B-432D-80D2-3CBB183D6A56 Q37616743-427C4815-C0C7-42C4-814C-77654B7C3803 Q37628185-C539BC79-1EE1-44A2-A1BD-949B8C4072DD Q37680966-ED8837EC-5F3B-4E15-883A-CA111A237CB9 Q37712385-AE852B06-8DC0-4368-A412-354F2200E986 Q37730812-51EF0FD9-EC64-4BA0-B19B-D49526E2A000 Q37745263-F67CDF07-C545-4E75-AB23-9951F11B7FBC Q38400073-2C09ADC8-9761-4652-88D7-674948F7C085 Q38722425-BF742439-D663-440B-9E32-89AF5465845B Q38733932-D0D76512-6081-4481-9730-91CA20F4509B Q38841939-F20B9E58-4533-4423-B707-AE88142F38DE Q38981383-2FC42282-74CA-4970-83AB-826B5E416809 Q38988997-A331DB2D-CB41-4546-8978-CDDBB2DEE37E Q39029043-E806E94E-7FE2-4F70-B46F-115427E4BB21 Q39195305-0C98E877-D223-4FF3-AA79-AF9430B62D74 Q39339912-72B823BF-9155-4D33-8356-EC228B328B84 Q39346505-56B83CC1-65AE-4952-9B3F-B1130B9A35F8 Q40298095-83A75530-6F00-4761-98F4-711B79D05344 Q40366413-B705F219-740E-412F-B00F-19CEA7EF6588 Q41447264-41D00A55-8C00-4F52-A439-DB906F137D70 Q41670949-BE5C5CB9-EEFB-4286-8163-25DB0E462227 Q42113451-91A6154B-F9D1-4751-92F4-918391CE1C45 Q42321342-E62810C0-8D05-4BB4-A822-F0C3723DE240 Q42380337-F9266DD2-7C0D-44FC-A771-7896162130A3 Q42421273-22795C46-B19B-4A36-9AB2-65175B2FA81E Q46047154-83523296-6313-49CF-9AF1-8D5E890679DE Q46271507-9C9B6F32-6104-4F1A-AE4B-2AA963799077 Q47112052-9CF2449B-EBA0-401F-A1E6-7706ADD836B1 Q47155204-06FB9FEB-3DDD-44BE-A849-D3CDB0142511 Q47167746-0D4E6015-01A8-4E73-9992-3FEC8E0BC8A7 Q47250561-53AC5A11-30AB-4572-9043-6A57AB77E940

P2860

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

http://www.wikidata.org/entity/Q26797238

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Clinical development of galuni ...... factor-beta signaling pathway

@ast

Clinical development of galuni ...... factor-beta signaling pathway

@en

Clinical development of galuni ...... factor-beta signaling pathway

@nl

type

label

Clinical development of galuni ...... factor-beta signaling pathway

@ast

Clinical development of galuni ...... factor-beta signaling pathway

@en

Clinical development of galuni ...... factor-beta signaling pathway

@nl

prefLabel

Clinical development of galuni ...... factor-beta signaling pathway

@ast

Clinical development of galuni ...... factor-beta signaling pathway

@en

Clinical development of galuni ...... factor-beta signaling pathway

@nl

P1433

Q26797238-6A8BD44A-29C6-4E61-93FC-354586624DD4

P1476

Q26797238-35D88FFF-7E4B-49BA-A007-FD9E59851442

P2093

Q26797238-1A5A2B67-6444-490C-AA8A-7EE139CBEACB

Q26797238-50C9DD9B-D89A-4848-A21A-041B4A353D87

Q26797238-5F6B282E-65DC-4043-ABE1-96FAE6F17341

Q26797238-83F1C0E3-0E67-41E0-A6E5-C9E8BDA8D1A4

Q26797238-89ED56D8-FCCF-4268-BEAF-3157E8226FE8

Q26797238-911179AB-97C9-4315-9785-B27C7847AFD9

Q26797238-9BFB5839-285B-41E3-98A0-9692DCFE771F

Q26797238-AB9A88AF-9F8B-45F6-8F8F-692304964219

Q26797238-C82D7DB6-5A03-4485-AB1E-D8CBF01BA47D

Q26797238-CD96B40A-170C-4B67-A77B-62434BEF3F6B

P275

Q26797238-30DF7BD8-DA0A-4500-917F-0A7805D6BBAF

P2860

Q26797238-00B69583-E8F6-4A9C-8363-A6CA71A7D317

Q26797238-03764B53-5EE4-444D-891E-C4A4915546A2

Q26797238-062AB782-0C3A-40CB-84D6-CCEDDAA85B44

Q26797238-0667AFA1-1D36-40E7-A49F-C601F1A4A893

Q26797238-08953850-6C52-4D94-97F4-B8101811F7CE

Q26797238-0C331C58-192B-4009-8754-EC9ADF19F007

Q26797238-0C6396B8-3649-4DBA-A1D4-0679C39DD503

Q26797238-0ED9D7BD-6AB5-4AFB-9C97-6F5B89CB046C

Q26797238-11E26FC6-D6B1-4C6E-A29A-33281F0BC8B5

Q26797238-121639C2-E4ED-4E61-8C74-3C5972929E96

P304

Q26797238-FF7E8776-5628-4B44-8C9A-133F115B1B53

P31

Q26797238-9F385CFD-82BE-48D9-BD70-97DD0D421D0D

Q26797238-A87FD8BE-0967-4DB6-A0F3-BBADBBC6BC48

P3181

Q26797238-C4267E5E-E40C-4E90-BEA0-4CCB858BD139

P356

Q26797238-57B40C45-21DA-4DAA-A0D3-BEBAC06E3474

P407

Q26797238-2725FA2A-D740-467F-9D78-593F71E0BAC8

P478

Q26797238-7BFD84F3-54BD-48BA-B8E8-5813BCE05838

P5008

Q26797238-CCC0419C-5C39-426E-902D-3304888680EB

P577

Q26797238-72803C5A-D86A-412D-A9F4-D082E6873E29

P698

Q26797238-58259E86-0A08-468D-9025-F1402A2771B6

P921

Q26797238-40AFF471-CCCD-4EC5-BF97-7B294DD9B0A7

Q26797238-7577A517-E332-4D30-9CA0-12A9A752B2F1

Q26797238-8812FE3D-03AF-425E-82BC-60AB6C26E47B

Q26797238-8B8F6BFD-6CC7-4BA9-B604-908B1B6D144B

Q26797238-9841F4AD-7D32-4735-BA5F-7141B26B5E17

Q26797238-DE4D35E0-5584-4DF0-B41D-98D4DE1839A2

Q26797238-F889C259-5CB0-4FC1-B9E3-3722F765B1EE

Q26797238-F9A73824-F474-42D5-8E21-17485D1FA38C

Q26797238-FBA3A4B2-1B59-4788-BCB4-4187AD7C924D

P932

Q26797238-CA2CFE23-5D56-4D54-98F9-A16BCD08745D

P3181

P356

P1433

Drug Design, Development and Therapy

P1476

Clinical development of galuni ...... factor-beta signaling pathway

@en

P2093

Anja J Stauber

http://www.w3.org/2001/XMLSchema#string

Ann L Cleverly

http://www.w3.org/2001/XMLSchema#string

Christopher A Slapak

http://www.w3.org/2001/XMLSchema#string

Durisala Desaiah

http://www.w3.org/2001/XMLSchema#string

Ivelina Gueorguieva

http://www.w3.org/2001/XMLSchema#string

J Scott Sawyer

http://www.w3.org/2001/XMLSchema#string

Karim A Benhadji

http://www.w3.org/2001/XMLSchema#string

Kyla E Driscoll

http://www.w3.org/2001/XMLSchema#string

Michael M Lahn

http://www.w3.org/2001/XMLSchema#string

Shawn T Estrem

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Hallmarks of Cancer: The Next Generation

TGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairs

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

TGF beta signals through a heteromeric protein kinase receptor complex

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Signal processing in the TGF-beta superfamily ligand-receptor network

Molecular mechanisms of epithelial-mesenchymal transition

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

TGFbeta signaling in growth control, cancer, and heritable disorders

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

P304

4479-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1875111

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/DDDT.S86621

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26309397

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

cell surface receptor

mechanism of action

membrane proteins

biomedical investigative technique

P932

4539082

http://www.w3.org/2001/XMLSchema#string